Fig. 3.
![Fig. 3. Thalidomide reduced myeloma tumor burden only in SCID-hu hosts implanted with human liver. / Sections (stained with hematoxylin and eosin) of decalcified human bones of CMC control (A,C) and thalidomide-treated (B,D) hosts inoculated with myeloma cells from patient 9. Note marked decrease in myeloma infiltration in the section from a host implanted with human liver (SCID-hu B+L, [D]) and no change in the section from SCID-hu B (B) compared with their respective CMC-treated (SCID-hu B+L, [C] and SCID-hu B, [A]) controls.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/100/12/10.1182_blood-2002-03-0939/5/h82323503003.jpeg?Expires=1722388219&Signature=WRB2T57PJeof8gtG6YcA3ospuUVKfhgmlFs-IBqwJxePOlV6ny44H6AoTmIf64PywdURY8i3atR~4r2KsDmoiuCJYrWvs8nnPf~KHkwOOjzpY4hyHxRtLb9q~tfgl-0w~eHkAVfFN5tgFdsUKphjeqLqC6W6M6GT0nFiBybYYTdnecVB7IKGKZeJ9fGkVVZ4vFRAwdkzWT3pcEFg0i-3pMeo5gbmPqetoYkCVp4kMOaDHXeKsb6RQ9dh1F9oYKHxApKTVyYD~GaF0N0N3edSzEg0TzhUJKMhDU4ZxpvTLyRYwQVz6Wc73sSA0u2DTKR~URupoaCveSSjhwYDpNVX6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Thalidomide reduced myeloma tumor burden only in SCID-hu hosts implanted with human liver.
Sections (stained with hematoxylin and eosin) of decalcified human bones of CMC control (A,C) and thalidomide-treated (B,D) hosts inoculated with myeloma cells from patient 9. Note marked decrease in myeloma infiltration in the section from a host implanted with human liver (SCID-hu B+L, [D]) and no change in the section from SCID-hu B (B) compared with their respective CMC-treated (SCID-hu B+L, [C] and SCID-hu B, [A]) controls.
